London-based HealthTech startup Level Zero Health immediately introduced a €6.6 million pre-Seed funding spherical to allow distant and steady hormone monitoring, utilizing distinctive DNA-based sensors.
The funding spherical was led by European VC redalpine. HAX (SOSV), Entrepreneur First, with business consultants additionally contributing to the spherical.
Ula Rustamova, CEO of Degree Zero Well being, feedback: “Our progressive distant monitoring know-how marks an unlimited leap ahead in hormone testing, and this funding will allow us to carry this revolutionary resolution to market.
“This breakthrough in well being know-how has come about in a comparatively quick period of time, however already we’re seeing robust demand from prospects who recognise the advantages of hormone monitoring not solely as a result of it permits sufferers to skip invasive and inconvenient lab checks, but in addition as a result of it captures essential knowledge inaccessible earlier than.”
Based in 2023 by Ula Rustamova, ex-Palantir Enterprise Tech Lead and wearable startup founder, alongside Irene Jia, who developed medical units at Philips, Degree Zero Well being focuses on wearable know-how innovation and hormone well being. Its know-how makes use of proprietary processes for distant intermittent and steady hormone monitoring.
The corporate has assembled a medical advisory board of consultants, together with Aaron Styer, medical director at CCRM Fertility and an affiliate professor at Harvard Medical Faculty, and Kelly Walker, a board-certified urologist and medical advisor at hims. Joshua Klein, medical director at Lengthen Fertility and assistant professor in reproductive science at Icahn Faculty of Medication at Mount Sinai.
In response to Degree Zero Well being, though hormones play a essential function in our well being, clinicians have relied solely on laboratory blood checks, which solely seize a single second in time and require specialised tools and experience.
Degree Zero Well being is altering this paradigm with its know-how that permits distant and steady hormone monitoring, opening up new prospects for understanding our physique’s chemistry.
As a substitute of invasive blood attracts, Degree Zero Well being’s DNA-based sensors detect hormone ranges in interstitial fluid – the fluid surrounding cells and tissues. In just below a 12 months, the corporate has validated its DNA-based sensors in simulated samples throughout 98% of the human medical vary, reportedly outpacing business requirements.
Degree Zero Well being combines biochemistry and nanotechnology in a glossy, minimally invasive wearable patch. Much like steady glucose displays, the machine attaches to the consumer’s arm and delivers real-time measurements of stress and reproductive hormones.
This development has the potential to rework a number of areas of healthcare, together with IVF, menopause and testosterone substitute remedy (TRT).
It can use the funding for R&D, bringing the product to market and increasing its workforce. Whereas initially focusing on B2B medical purposes, the corporate has positioned itself for potential B2C and pharma growth as effectively.
Philip Kneis, investor at redalpine and board member of Degree Zero Well being, stated: “We did it for blood strain and can do it once more for hormones. Steady hormone measurement is without doubt one of the holy grails of diagnostics, and as basic science transitions to engineering, we couldn’t be extra excited to again Degree Zero Well being of their mission to rework hormone monitoring with their novel biosensor – paving the way in which for a brand new period of personalised well being administration.”
Aaron Styer MD, Co-founding companion and medical director at CCRM Fertility Boston feedback: “Enhancements in healthcare supply have been impacted by the constraints of current units and purposes. This technological breakthrough by Degree Zero Well being will remodel the clinician’s means to handle and monitor hormonal-based ailments and coverings. The know-how has a myriad of purposes throughout distant hormonal monitoring for fertility therapies and endocrine problems. It can considerably broaden affected person entry to care, cut back healthcare prices, and allow clinicians to alter the paradigm of medical follow.”
